CSIMarket
 
Ngm Biopharmaceuticals Inc   (NGM)
Other Ticker:  
 
 
Price: $1.5700 $0.04 2.614%
Day's High: $1.58 Week Perf: 1.95 %
Day's Low: $ 1.53 30 Day Perf: 6.8 %
Volume (M): 1,176 52 Wk High: $ 4.69
Volume (M$): $ 1,846 52 Wk Avg: $2.09
Open: $1.53 52 Wk Low: $0.60



 Market Capitalization (Millions $) 129
 Shares Outstanding (Millions) 82
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -142
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 1

Ngm Biopharmaceuticals Inc
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on developing transformative therapeutics for serious diseases. The company utilizes its expertise in biology, chemistry, and immunology to discover and develop novel therapies.

NGM Biopharmaceuticals is known for its innovative approach to drug discovery, using cutting-edge technology and advanced research techniques to identify targets and potential therapeutic candidates. The company's pipeline includes therapies for several indications, including liver diseases, ophthalmology, and cancer.

NGM Biopharmaceuticals has a strong commitment to improving patient outcomes and addressing unmet medical needs. The company's mission is to develop safe and effective therapies that make a meaningful impact on patients' lives.

Overall, NGM Biopharmaceuticals Inc is a dynamic biopharmaceutical company with a robust pipeline and a focus on innovative drug discovery to address critical diseases.


   Company Address: 333 Oyster Point Boulevard South San Francisco 94080 CA
   Company Phone Number: 243-5555   Stock Exchange / Ticker: NASDAQ NGM
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Ngm Biopharmaceuticals Inc

NGM Biopharmaceuticals, Inc. Faces Steep Decline in Revenue Amid Merger Agreement with The Column Group

NGM Biopharmaceuticals, Inc. (NGM Bio) has recently made a significant move in the biotechnology industry with its merger agreement with The Column Group. This merger marks a milestone in NGM Bio's quest to revolutionize patient care through its groundbreaking therapeutics. The merger agreement involves Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc., both of which are affiliated with The Column Group, LP, acquiring NGM Bio through a cash tender offer. NGM Bio's longest and largest stockholder, The Column Group, LP, holds approximately 26% of the company's outstanding shares.
In terms of financial performance, NGM Bio reported a decrease in loss per share for the fourth quarter of 2023 compared to the previous year. The company also showed improvement in EPS from the prior quarter. However, the revenue dropped sharply by -99.092% to $0.17 million from $18.18 million in the same quarter a year ago. Sequentially, the revenue tumbled by -71.649% from $0.58 million. NGM Bio reported a net shortfall of $-27.670 million for the fourth quarter of 2023, compared to a deficit of $-36.437 million in the same quarter the previous year. The company indicated a net loss of $-142.38 million for the financial year 2023, with revenue of $4.42 million.

Merger and Acquisition

NGM Bio Joins Forces with Affiliates of The Column Group, LP to Redefine Biotechnology

Published Mon, Feb 26 2024 2:04 PM UTC

NGM Bio's Merger Agreement: Revolutionizing Biotechnology with The Column Group
SAN FRANCISCO, Feb. 26, 2024 - NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a groundbreaking biotechnology company renowned for its transformative therapeutics, has recently announced a game-changing move in the industry. NGM Bio has entered into a definitive Agreement and Plan of Me...

Clinical Study

NGM Bio's Promising Clinical Data for NGM707 and Strategic Focus on Rare Conditions with Unmet Need

Published Tue, Jan 9 2024 1:00 PM UTC

NGM Biopharmaceuticals, Inc. (NGM Bio), a prominent biotechnology company dedicated to revolutionizing therapeutic options for patients, recently shared promising clinical findings from an ongoing Phase 1 Part 1b study involving NGM707, a remarkable dual ILT2/ILT4 antagonist antibody candidate. Furthermore, NGM Bio presented its strategic plan to refocus the clinical develop...

Ngm Biopharmaceuticals Inc

Catastrophic Plunge: Ngm Biopharmaceuticals Inc's Top-Line Tanks by -92.643% in Q3 2023

Ngm Biopharmaceuticals Inc, a major player in the pharmaceutical preparations industry, has released its financial report for the most recent fiscal period. Despite facing a decline in revenue, the company managed to decrease its loss per share compared to the preceding year.
In terms of the loss per share, Ngm Biopharmaceuticals Inc reduced it from $-0.59 to $-0.35 per share, indicating an improvement in performance. Additionally, the EPS improved from $-0.46 per share in the previous reporting period. This positive development shows the company's ability to manage its expenses more effectively.
However, the company faced a significant decrease in revenue, with a -92.643% drop from $7.91 million in the corresponding reporting period a year prior to $0.58 million in the most recent period. Sequentially, the revenue tumbled by -59.1% from $1.42 million. This decline can be attributed to various factors, including market fluctuations and industry trends.

Ngm Biopharmaceuticals Inc

Ngm Biopharmaceuticals Witnesses Promising Financial Advancements Despite Challenging Quarter

As a stock market journalist, I have been closely monitoring the financial results of Ngm Biopharmaceuticals Inc during the second quarter of 2023 earnings season. The company has certainly shown some promising improvements compared to the previous year.
Starting with the earnings per share, Ngm Biopharmaceuticals Inc has managed to decrease its loss from $-0.59 per share in the same period last year to $-0.46 per share this year. This signifies a positive trend and may indicate that the company is making strides towards profitability. Furthermore, the income per share has also improved, moving from $-0.58 per share in the previous reporting season to an undisclosed positive figure.






 

Ngm Biopharmaceuticals Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Ngm Biopharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Ngm Biopharmaceuticals Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com